Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study.
Authors
Tobin, William OliverKinsella, Justin A
Collins, Daniel Ronan
Coughlan, Tara
O'Neill, Desmond
Egan, Bridget
Tierney, Sean
Feeley, Thomas Martin
Murphy, Raymond P
McCabe, Dominick J H
Affiliation
Department of Neurology, The Adelaide and Meath Hospital/National Children's, Hospital, Tallaght, Dublin, UK.Issue Date
2012-02-01T10:49:11ZMeSH
AdultAged
Aspirin/*pharmacology/therapeutic use
Blood Platelets/*drug effects/physiology
Blood Specimen Collection/methods
Dipyridamole/*pharmacology/therapeutic use
Drug Therapy, Combination
Female
Humans
Ischemic Attack, Transient/*blood/drug therapy
Longitudinal Studies
Male
Middle Aged
Platelet Activation/drug effects
Platelet Aggregation Inhibitors/*pharmacology/therapeutic use
Platelet Function Tests
Stroke/*blood/drug therapy
Metadata
Show full item recordCitation
Br J Haematol. 2011 Mar;152(5):640-7. doi: 10.1111/j.1365-2141.2010.08539.x. Epub, 2011 Jan 12.Journal
British journal of haematologyDOI
10.1111/j.1365-2141.2010.08539.xPubMed ID
21223254Abstract
Ex vivo dipyridamole 'non-responsiveness' has not been extensively studied in ischaemic cerebrovascular disease. Platelet surface marker expression, leucocyte-platelet complex formation and inhibition of platelet function at high shear stress as detected by the PFA-100(R) Collagen-Adenosine-diphosphate (C-ADP) and Collagen-Epinephrine cartridges was assessed in 52 patients within 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke on aspirin, and then 14 d (14 d) and >90 d (90 d) after adding dipyridamole. A novel definition of 'Dipyridamole non-responsiveness' was used. The median C-ADP closure time increased following addition of dipyridamole, remained elevated at 90 d (P /= 0.5), at 14 and 90 d versus baseline. Additional inhibition of platelet function has been detected with the PFA-100 when dipyridamole is added to aspirin. Elevated monocyte-platelet complexes may contribute to ex vivo dipyridamole non-responsiveness.Language
engISSN
1365-2141 (Electronic)0007-1048 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1111/j.1365-2141.2010.08539.x
Scopus Count
Collections
Related articles
- Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
- Authors: McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM
- Issue date: 2005 Aug
- High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study.
- Authors: Tobin WO, Kinsella JA, Coughlan T, Collins DR, O'Neill D, Murphy RP, Egan B, Tierney S, Feeley TM, McCabe DJ
- Issue date: 2013 Feb
- Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
- Authors: Kinsella JA, Tobin WO, Cox D, Coughlan T, Collins R, O'Neill D, Murphy RP, McCabe DJ
- Issue date: 2013 Oct
- Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
- Authors: Serebruany VL, Malinin AI, Pokov AN, Hanley DF
- Issue date: 2008 Feb
- Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
- Authors: Serebruany VL, Malinin AI, Oshrine BR, Sane DC, Takserman A, Atar D, Hennekens CH
- Issue date: 2004